What does Congruence Therapeutics do?
Congruence Therapeutics is a clinical-stage biotechnology company that discovers and develops small molecule correctors and allosteric modulators to address and correct disease conditions at the molecular level.
What is Congruence’s core focus?
The company focuses on genetically-validated human diseases caused by protein misfolding and abnormal signaling.
What makes Congruence different from other biotech companies?
Congruence has developed a computational discovery engine that uniquely identifies hidden binding sites on proteins, models conformational dynamics, and rationally designs small molecules that correct protein structure and function.
What stage is Congruence Therapeutics at?
Congruence is a clinical-stage company with a pipeline of drug candidates targeting genetically validated proteins.
Who are Congruence’s investors?
Congruence is supported by leading institutional life sciences investors.
What is the Revenir™ platform?
Revenir™ is a computational drug discovery platform that models proteins across multiple conformations to identify novel binding sites for small molecule drug design.
How does Revenir™ work?
Revenir™ analyzes protein dynamics, identifies allosteric and cryptic pockets, and enables virtual screening to design new small molecule therapies.
What are allosteric binding sites?
Allosteric binding sites are regions of a protein that regulate its activity when bound by a molecule, often distinct from the primary active site.
What are cryptic pockets?
Cryptic pockets are hidden binding sites that appear only under certain protein conformations and are not easily detected by traditional methods.
Why are hidden binding sites important for drug discovery?
They enable the targeting of proteins that are considered difficult to drug when using conventional approaches.
How does Congruence integrate computation and experiments?
The company uses computational predictions to design molecules, which are then validated through experimental assays.
What is protein misfolding?
Protein misfolding occurs when a protein fails to adopt its correct three-dimensional structure, which can impair its function and lead to disease.
Why does protein misfolding cause disease?
Misfolded proteins can lose function, aggregate, or disrupt cellular processes, contributing to conditions such as neurodegeneration and metabolic disorders.
What are small molecule correctors?
Small molecule correctors are compounds that bind to proteins and stabilize their structure or activity, restoring normal function.
What does it mean to restore protein function?
Restoring protein function involves correcting folding, improving stability, or enhancing activity so the protein can perform its normal biological role.
What is a genetically validated target?
A genetically validated target is a protein where mutations are directly linked to disease, increasing confidence that modulating it will have therapeutic benefit.
What diseases does Congruence target?
Congruence targets diseases driven by protein dysfunction, including genetic obesity, GBA-associated Parkinson’s disease, and α1-antitrypsin deficiency.
What is GBA Parkinson’s disease?
GBA Parkinson’s disease is a form of Parkinson’s associated with mutations in the GBA gene, which impair lysosomal function.
Why is GCase an important target in Parkinson’s disease?
GCase is genetically linked to Parkinson’s disease and plays a key role in lysosomal function and control of substrate levels.
What is α1-antitrypsin deficiency?
A1AT deficiency is a genetic disorder where misfolded proteins accumulate in the liver leading to its damage, and failure to protect the lungs.
Why are these targets considered difficult to drug?
They often involve intracellular proteins or misfolding mechanisms that are not accessible using traditional drug discovery approaches.
Yes, Congruence partners with pharmaceutical companies to apply its platform across multiple therapeutic areas. For example, Congruence is currently advancing a multi-target research collaboration with Ono Pharmaceuticals in which it is leading the effort to discover small molecule correctors and allosteric modulators for targets spanning oncology, immunology and neurology. Congruence has a separate research collaboration in place with an undisclosed large pharmaceutical company in which Congruence is leading the discovery effort for a high-value metabolic target. For more information, please contact Frank Taffy, Chief Business Officer, at ftaffy@congruencetx.com.
What types of partnerships does Congruence pursue?
The company engages in multi-target collaborations focused on discovering small molecule correctors and modulators.
What therapeutic areas do partnerships cover?
Current collaborations span oncology, metabolic diseases, neurology, and immunology.
Headquarters Location
6666 Saint-Urbain Street, Suite 450, Montreal, Quebec, H2S 3H1,Canada
US Location
Congruence Therapeutics USA Inc.
1340 Environ way, Suite 306, Chapel Hill, NC, 27517
"*" indicates required fields